Lemaitre Vascular Inc. logo

Lemaitre Vascular Inc. (LMAT)

Market Closed
3 Jun, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
91. 61
-0.01
-0.01%
$
2.19B Market Cap
46.73 P/E Ratio
0.64% Div Yield
25,742 Volume
1.65 Eps
$ 91.62
Previous Close
Add Transaction
Day Range
90.96 93.39
Year Range
79.01 118.01
Want to track LMAT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
LeMaitre Vascular, Inc. (LMAT) Q2 2025 Earnings Call Transcript

LeMaitre Vascular, Inc. (LMAT) Q2 2025 Earnings Call Transcript

LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants David B. Roberts - President & Director Dorian LeBlanc - Chief Financial Officer George W.

Seekingalpha | 10 months ago
LeMaitre Vascular (LMAT) Beats Q2 Earnings and Revenue Estimates

LeMaitre Vascular (LMAT) Beats Q2 Earnings and Revenue Estimates

LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.6 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.52 per share a year ago.

Zacks | 10 months ago
LeMaitre Vascular, Inc. (LMAT) Q1 2025 Earnings Call Transcript

LeMaitre Vascular, Inc. (LMAT) Q1 2025 Earnings Call Transcript

LeMaitre Vascular, Inc. (LMAT) Q1 2025 Earnings Call Transcript

Seekingalpha | 1 year ago
LeMaitre Vascular (LMAT) Lags Q1 Earnings Estimates

LeMaitre Vascular (LMAT) Lags Q1 Earnings Estimates

LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.48 per share, missing the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.44 per share a year ago.

Zacks | 1 year ago
LeMaitre (LMAT) Soars 7.7%: Is Further Upside Left in the Stock?

LeMaitre (LMAT) Soars 7.7%: Is Further Upside Left in the Stock?

LeMaitre (LMAT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks | 1 year ago
3 Reasons Growth Investors Will Love LeMaitre (LMAT)

3 Reasons Growth Investors Will Love LeMaitre (LMAT)

LeMaitre (LMAT) could produce exceptional returns because of its solid growth attributes.

Zacks | 1 year ago
Best Momentum Stocks to Buy for March 4th

Best Momentum Stocks to Buy for March 4th

OPCH and LMAT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 4, 2025.

Zacks | 1 year ago
LeMaitre (LMAT) Upgraded to Buy: Here's What You Should Know

LeMaitre (LMAT) Upgraded to Buy: Here's What You Should Know

LeMaitre (LMAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks | 1 year ago
LeMaitre Vascular, Inc. (LMAT) Q4 2024 Earnings Call Transcript

LeMaitre Vascular, Inc. (LMAT) Q4 2024 Earnings Call Transcript

LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants J.J. Pellegrino - Chief Financial Officer George LeMaitre - Chief Executive Officer Dave Roberts - President Conference Call Participants Nathan Treybeck - Wells Fargo Danny Stauder - Citizens JMP Matthew Park - Cantor Fitzgerald Frank Takkinen - Lake Street Capital Markets Michael Petusky - Barrington Research Jim Sidoti - Sidoti & Company Operator Welcome to the LeMaitre Vascular Q4 2024 Financial Results Conference Call.

Seekingalpha | 1 year ago
LeMaitre Vascular (LMAT) Meets Q4 Earnings Estimates

LeMaitre Vascular (LMAT) Meets Q4 Earnings Estimates

LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.49 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.38 per share a year ago.

Zacks | 1 year ago
Final Trade: LMAT, GOOGL, IBM, GILD

Final Trade: LMAT, GOOGL, IBM, GILD

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

Youtube | 1 year ago
LeMaitre Vascular: The Market Is Catching On To This Dividend Growth Story

LeMaitre Vascular: The Market Is Catching On To This Dividend Growth Story

LeMaitre continues to expand in the peripheral vascular disease market, with recent revenue gains driven by premium pricing and international growth. Its strong dividend growth of 14.3% this year and double-digit CAGR over the past five years are particularly appealing. With a high-margin, low-competition niche and accelerating geographic expansion, LeMaitre remains well-positioned for sustained growth.

Seekingalpha | 1 year ago
Loading...
Load More